CYTL1

CYTL1 is a small secreted chemokine-like protein that functions in cartilage homeostasis, immune cell chemotaxis, and tumor metabolic regulation (PMID:17644814, PMID:21652695, PMID:35115484). As an autocrine factor it promotes chondrogenic differentiation by stimulating Sox9 transcriptional activity and inducing IGF-1, and it drives chondrocyte redifferentiation through induction of Sox9 and Col2α1 (PMID:17644814, PMID:32736681); while dispensable for cartilage and bone development, CYTL1 maintains adult cartilage homeostasis, as its loss accelerates osteoarthritic cartilage destruction after joint destabilization (PMID:21652695). Biophysically the secreted protein adopts a predominantly beta-sheet, chemokine-like fold and elicits calcium flux in chondrocytes (PMID:28478073), and it signals through the chemokine receptor CCR2 to chemoattract monocytes via ERK and to activate neutrophil chemotaxis, phagocytosis, and ROS release via Akt phosphorylation (PMID:31069137, PMID:31823178). A signal-peptide-lacking intracellular isoform (ΔCYTL1) suppresses glycolytic reprogramming in breast cancer by competitively binding the N-terminus of NDUFV1 to block MDM2-mediated proteasomal degradation, stabilizing NDUFV1 to raise NAD+ and attenuate Src-dependent LDHA phosphorylation (PMID:35115484); CYTL1 additionally activates Nrf2 through autophagic Keap1 degradation, transactivating CBS to support transsulfuration-dependent cysteine synthesis and protect cells from ferroptosis (PMID:38211443). CYTL1 further modulates the TGF-β/CCN2 axis to promote M2 macrophage polarization in lung fibrosis (PMID:39103233).

1. 2007 High

   Established CYTL1 as a functional autocrine chondrogenic factor rather than an orphan cytokine-like sequence, defining its first molecular activity.

   Evidence Exogenous protein and lentiviral overexpression in mesenchymal micromass culture with Sox9 reporter and IGF-1 expression readouts

   PMID:17644814

   Open questions at the time

   • Receptor mediating the chondrogenic signal not identified
   • Mechanism linking CYTL1 to Sox9 activation unresolved
2. 2011 High

   Distinguished CYTL1's developmental dispensability from its homeostatic role, showing it protects mature cartilage rather than building it.

   Evidence Cytl1-/- knockout mice analyzed in a destabilization of the medial meniscus osteoarthritis model with histology

   PMID:21652695

   Open questions at the time

   • Molecular pathway protecting cartilage not defined
   • No connection to a receptor or downstream effector established
3. 2011 Low

   Proposed a structural basis for receptor engagement by predicting an IL8/CCL2-like chemokine fold and CCR2-relevant features.

   Evidence Computational molecular modeling compared with CCL2 structure

   PMID:21322034

   Open questions at the time

   • Computational prediction only, no experimental structure or binding validation
   • CCR2 binding not demonstrated experimentally here
4. 2017 Medium

   Provided experimental biophysical support for a chemokine-like fold and demonstrated functional signaling output in chondrocytes.

   Evidence Bacterially produced recombinant CYTL1 analyzed by circular dichroism, calcium flux, and proteoglycan binding assays

   PMID:28478073

   Open questions at the time

   • High-resolution structure absent
   • Limited proteoglycan affinity leaves signaling/localization mechanism unclear
5. 2016 Medium

   Extended CYTL1 function to reproductive tissue, implicating it in endometrial receptivity and embryo implantation.

   Evidence Hormone-regulated endometrial expression analysis with proliferation, LIF/HB-EGF secretion, and spheroid adhesion assays

   PMID:26800213

   Open questions at the time

   • Receptor and signaling pathway in endometrium not identified
   • Single-lab cell-based assays
6. 2019 Medium

   Defined a CCR2/ERK signaling axis for monocyte chemoattraction and revealed an anti-metastatic role via STAT3 suppression.

   Evidence Recombinant and overexpressed CYTL1 in migration/invasion assays, STAT3 phosphorylation, and breast cancer metastasis mouse models

   PMID:31069137

   Open questions at the time

   • Direct CYTL1-CCR2 binding not biochemically confirmed
   • Link between chemoattraction and tumor suppression incompletely connected
7. 2020 Medium

   Generalized CCR2-mediated signaling to neutrophils and added Akt phosphorylation and ROS output to the effector repertoire.

   Evidence LPS-stimulated neutrophil phagocytosis, chemotaxis, Akt western blot, and ROS assays in vivo and in vitro

   PMID:31823178

   Open questions at the time

   • Direct receptor binding not shown
   • Relationship between ERK and Akt branches downstream of CCR2 unclear
8. 2020 Medium

   Reinforced the chondrogenic mechanism by showing recombinant CYTL1 drives chondrocyte redifferentiation across cartilage developmental stages.

   Evidence Recombinant protein treatment of chondrocytes with qRT-PCR for Sox9, Col2α1, Col1α1 and developmental expression analysis

   PMID:32736681

   Open questions at the time

   • Receptor/signaling intermediates not identified
   • In vivo relevance to redifferentiation untested
9. 2022 High

   Revealed an intracellular, receptor-independent function of a signal-peptide-lacking isoform that suppresses tumor glycolysis through protein stabilization.

   Evidence ΔCYTL1 overexpression with Co-IP, MDM2 ubiquitination/degradation assays, NDUFV1-Src interaction, LDHA phosphorylation, and tumor models

   PMID:35115484

   Open questions at the time

   • Regulation switching between secreted and intracellular isoforms unknown
   • Structural basis of NDUFV1 N-terminal competition not resolved
10. 2024 High

    Connected CYTL1 to redox/ferroptosis control via a Keap1-Nrf2-CBS axis supporting cysteine biosynthesis.

    Evidence CYTL1 knockdown/overexpression with autophagy flux, Nrf2 target assays, CBS activity, ferroptosis assays, and CBS silencing rescue in vitro and in vivo

    PMID:38211443

    Open questions at the time

    • Mechanism by which CYTL1 promotes autophagic Keap1 degradation unclear
    • Whether this is intracellular or secreted CYTL1 not delineated
11. 2024 Medium

    Implicated CYTL1 in fibrotic remodeling through TGF-β/CCN2-driven M2 macrophage polarization.

    Evidence CYTL1 ablation in bleomycin-induced lung fibrosis with M2 marker, CCN2 analysis, and TGF-β inhibitor phenocopy

    PMID:39103233

    Open questions at the time

    • Direct molecular target of CYTL1 in the TGF-β/CCN2 axis unknown
    • Cell type producing CYTL1 in fibrosis not defined
12. 2024 Medium

    Extended CYTL1 function to vascular control, mediating arteriolar vasodilation and angiogenic remodeling from neuro-endothelial cells.

    Evidence Intravital multiphoton imaging of optogenetic mice with NEC gain/loss-of-function and single-cell transcriptomics (preprint)

    PMID:bio_10.1101_2024.09.30.615824

    Open questions at the time

    • Preprint not yet peer-reviewed
    • Molecular receptor/effector for vasodilation not defined in available evidence

• How CYTL1 partitions between a secreted CCR2-dependent ligand and an intracellular isoform, and whether a single receptor mediates its diverse chemotactic, chondrogenic, and vascular effects, remains unresolved.
• No experimental demonstration of direct CYTL1-CCR2 binding in the corpus
• Regulation of isoform choice (secreted vs. signal-peptide-lacking) uncharacterized
• No high-resolution structure of CYTL1 or its complexes